Alla Sridhar, Mason Deborah F
New Zealand Brain Research Institute, University of Otago, 66 Stewart Street, Christchurch 8011, New Zealand.
Department of Neurology, Christchurch Hospital, Christchurch, New Zealand.
J Clin Neurosci. 2014 Aug;21(8):1288-91. doi: 10.1016/j.jocn.2013.09.009. Epub 2013 Nov 4.
New Zealand (NZ) is a high risk country for multiple sclerosis (MS) with an overall age and sex standardised prevalence of 73.1 per 100,000 population. The age and sex standardised prevalence within the Māori population is substantially lower at 24.2 per 100,000 population. A latitudinal gradient exists with MS prevalence increasing threefold from the North (37°S) to the South (48°S) of NZ. Over 1600 (56.8%) persons with MS experience moderate to severe disability. Despite the high prevalence of MS and the significant degree of disability experienced by people with MS, the availability and prescribing guidelines for MS disease modifying treatments are more restrictive in NZ than in other developed nations.
新西兰（NZ）是多发性硬化症（MS）的高风险国家，总体年龄和性别标准化患病率为每10万人73.1例。毛利人群体中的年龄和性别标准化患病率则低得多，为每10万人24.2例。新西兰存在纬度梯度，MS患病率从北（南纬37°）到南（南纬48°）增加了两倍。超过1600名（56.8%）MS患者有中度至重度残疾。尽管MS患病率高，且MS患者有显著程度的残疾，但与其他发达国家相比，新西兰MS疾病修正治疗的可及性和处方指南更为严格。
